{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:23:18Z","timestamp":1789705398423,"version":"4.0.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01368-9","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T06:34:07Z","timestamp":1759818847000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Outcomes of older patients with TP53-mutated myeloid neoplasms"],"prefix":"10.1038","volume":"15","author":[{"given":"Omer","family":"Jamy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mobachir","family":"El Kettani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kashish","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory M.","family":"Shallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendall","family":"Diebold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Coltoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron D.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0296-8686","authenticated-orcid":false,"given":"Anand","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3352-0902","authenticated-orcid":false,"given":"Jan P.","family":"Bewersdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Foucar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-7912","authenticated-orcid":false,"given":"Yasmin","family":"Abaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Palmisiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9163-8792","authenticated-orcid":false,"given":"Adam S.","family":"DuVall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5290-9289","authenticated-orcid":false,"given":"Vamsi","family":"Kota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8208-1902","authenticated-orcid":false,"given":"Shyam A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehab","family":"Atallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-6302","authenticated-orcid":false,"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1548-918X","authenticated-orcid":false,"given":"Talha","family":"Badar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"1368_CR1","doi-asserted-by":"crossref","unstructured":"Zeidner JF, Sallman DA, R\u00e9cher C, Daver NG, Leung AY, Hiwase DK, et al. Magrolimab plus azacitidine vs physician\u2019s choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study. Blood. 2025;146:590\u2013600.","DOI":"10.1182\/blood.2024027408"},{"key":"1368_CR2","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1182\/blood.2022018236","volume":"141","author":"D Hiwase","year":"2023","unstructured":"Hiwase D, Hahn C, Tran ENH, Chhetri R, Baranwal A, Al-Kali A, et al. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype. Blood. 2023;141:1087\u201391.","journal-title":"Blood"},{"key":"1368_CR3","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/s41409-023-01977-7","volume":"58","author":"O Jamy","year":"2023","unstructured":"Jamy O, Diebold K, Davis K, Bachiashvili K, Rangaraju S, Vachhani P, et al. Impact of induction intensity and transplantation on outcomes of patients with complex karyotype and TP53-mutated acute myeloid leukemia. Bone Marrow Transpl. 2023;58:823\u20135.","journal-title":"Bone Marrow Transpl"},{"key":"1368_CR4","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/ajh.27609","volume":"100","author":"A Tefferi","year":"2025","unstructured":"Tefferi A, Abdelmagid M, Loscocco GG, Fathima S, Begna KH, Al-Kali A, et al. TP53 mutations in myeloproliferative neoplasms: context-dependent evaluation of prognostic relevance. Am J Hematol. 2025;100:552\u201360.","journal-title":"Am J Hematol"},{"key":"1368_CR5","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1182\/blood.2024025409","volume":"144","author":"H D\u00f6hner","year":"2024","unstructured":"D\u00f6hner H, DiNardo CD, Appelbaum FR, Craddock C, Dombret H, Ebert BL, et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024;144:2169\u201373.","journal-title":"Blood"},{"key":"1368_CR6","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"1368_CR7","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"1368_CR8","doi-asserted-by":"publisher","first-page":"E232","DOI":"10.1002\/ajh.26546","volume":"97","author":"T Badar","year":"2022","unstructured":"Badar T, Atallah E, Shallis RM, Goldberg AD, Patel A, Abaza Y, et al. Outcomes of TP53-mutated AML with evolving frontline therapies: impact of allogeneic stem cell transplantation on survival. Am J Hematol. 2022;97:E232\u2013e5.","journal-title":"Am J Hematol"},{"key":"1368_CR9","doi-asserted-by":"crossref","unstructured":"Baranwal A, Langer K, Gannamani V, Rud D, Cibich A, Saygin C, et al. Factors associated with survival following allogeneic transplantation for myeloid neoplasms harboring TP53 mutations. Blood Adv. 2025;9:3395\u2013407.","DOI":"10.1182\/bloodadvances.2024015335"},{"key":"1368_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01000-2","volume":"14","author":"T Badar","year":"2024","unstructured":"Badar T, Nanaa A, Atallah E, Shallis RM, Guilherme SCC, Goldberg AD, et al. Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood Cancer J. 2024;14:32.","journal-title":"Blood Cancer J"},{"key":"1368_CR11","doi-asserted-by":"publisher","first-page":"4893","DOI":"10.1200\/JCO.22.02604","volume":"41","author":"NG Daver","year":"2023","unstructured":"Daver NG, Vyas P, Kambhampati S, Al Malki MM, Larson RA, Asch AS, et al. Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: phase Ib results. J Clin Oncol. 2023;41:4893\u2013904.","journal-title":"J Clin Oncol"},{"key":"1368_CR12","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1200\/JCO.20.02342","volume":"39","author":"T Cluzeau","year":"2021","unstructured":"Cluzeau T, Sebert M, Rahm\u00e9 R, Cuzzubbo S, Lehmann-Che J, Madelaine I, et al. Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe Francophone des My\u00e9lodysplasies (GFM). J Clin Oncol. 2021;39:1575\u201383.","journal-title":"J Clin Oncol"},{"key":"1368_CR13","unstructured":"https:\/\/ir.aprea.com\/news-releases\/news-release-details\/aprea-therapeutics-announces-results-primary-endpoint-phase-3 [press release]."},{"key":"1368_CR14","doi-asserted-by":"publisher","first-page":"4497","DOI":"10.1200\/JCO.23.00866","volume":"41","author":"J Versluis","year":"2023","unstructured":"Versluis J, Saber W, Tsai HK, Gibson CJ, Dillon LW, Mishra A, et al. Allogeneic hematopoietic cell transplantation improves outcome in myelodysplastic syndrome across high-risk genetic subgroups: genetic analysis of the blood and marrow transplant clinical trials network 1102 study. J Clin Oncol. 2023;41:4497\u2013510.","journal-title":"J Clin Oncol"},{"key":"1368_CR15","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1182\/bloodadvances.2024014499","volume":"9","author":"K Lontos","year":"2025","unstructured":"Lontos K, Saliba RM, Kanagal-Shamanna R, \u00d6zcan G, Ramdial J, Chen G, et al. TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS\/AML for transplantation. Blood Adv. 2025;9:2845\u201354.","journal-title":"Blood Adv"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01368-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01368-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01368-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T19:06:33Z","timestamp":1759863993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01368-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1368"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01368-9","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"OJ; Advisory board for Ascentage, Sobi, Maat, and TERN, AP; Research funding from Kronos Bio, Sumitomo, Servier, Incyte, Pfizer; Honoraria for advisory boards from Sobi, AbbVie. CF; Advisory board, Stemline, and Honoraria from Binaytara Foundation. CL; Advisory board for ADC Therapeutics, Autolus, Consulting: Rigel. SAP served on the Acute Leukemia Advisory Board for Syndax and the MDS Advisory Board for Bristol Myers Squibb.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted following approval from the Institutional Review Board (IRB #21-002315) and in accordance with the ethical principles outlined in the Declaration of Helsinki (1975, as revised in 2000). Informed consent was waived due to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"160"}}